# Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

> **NCT00295061** · PHASE3 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 24 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** Alpha-1 MP
- **DRUG:** alpha-1 proteinase inhibitor (human)

## Key facts

- **NCT ID:** NCT00295061
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295061, "Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00295061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*